

COVID-19 ANTIBODY TESTING: The Next Step for Government Authorities

The novel coronavirus disease (COVID-19) is a virus of global health significance caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At BioReference, our priority remains in the health and safety of the communities we serve, and we are doing our part to deliver answers during these uncertain times.

For government authorities, testing for antibodies is the next logical step to help guide decisions about moving forward. BioReference is proud to collaborate with host organizations to provide laboratory and testing services that help identify:

- If an individual has detectable COVID-19 antibodies
- How many people were infected in a geographic area
- How the number of infected people is changing over time
- Types of populations that may be at a higher risk of infection
- How many people were infected with mild or no symptoms

COVID-19 ANTIBODY TESTING FROM BIOREFERENCE

Antibodies are proteins produced by the body's immune system to try to fight infection. BioReference offers a test that utilizes a blood sample to measure SARS-CoV-2 specific antibody levels, which correlate with a patient's immune response after COVID-19 infection. Based on early evidence, antibodies are expected to be elevated in the majority of patients by 14 days after the onset of symptoms. The timeline for antibody elevation in asymptomatic patients is still being studied.

COVID-19 ANTIBODY TECHNOLOGY

BioReference offers an immunoassay for antibody testing with high sensitivity and specificity. Each COVID-19 antibody test is performed utilizing the Roche Elecsys Anti-Sars CoV-2 assay or the DiaSorin LIAISON® SARS-CoV-2 S1/S2 assay. These high-volume instruments have been verified for sensitivity and specificity. They have been approved by appropriate state Departments of Health, and are being used under FDA Emergency Use Authorizations (EUA).

ANTIBODY TESTING FOR GOVERNMENT AUTHORITIES

Test results play a critical role in the fight against COVID-19 by identifying who has detectable antibodies. Together with other clinical information and guidance from health authorities, these results can assist with decisions on ensuring the safety of employees and customers.

Many COVID-19 patients have mild or no symptoms, and may not have been diagnosed when infected. Antibody testing can provide government officials key information about who has been infected, and who may potentially be immune from re-infection when making decisions on returning to work and implementing workplace safety procedures.


TESTING PROCESS AND SCREENING EVENTS

To support return-to-work strategies and COVID-19 antibody screening efforts, BioReference is pleased to offer digital registration and check-in, onsite specimen collection and processing, online result access, and educational resources for employees.*


Digital Registration

BioReference provides a unique digital platform for online registration and test scheduling. The portal allows each individual to schedule a visit by location (if multiple sites are determined), and preferred date and time. The government entity overseeing the program will be responsible for communication with employees and sending a registration link.

Registration link sent to participants, and registration is completed within online portal




The participant registration information is captured and scheduled for a 1 hour timeslot




Check-In

After registration, employees will receive a QR code confirmation. Upon arrival at the facility, this QR code can be presented for easy arrival and check-in.

The participant arrives onsite at the screening event 15 minutes prior to their one hour timeslot and presents QR code for check-in



The participant's identification is verified and the test requisition is printed and provided to participant. The participant is directed to BioReference phlebotomist for sample collection.




Onsite Testing

Antibody testing is completed with a blood sample. BioReference is able to provide a host organization with on-site phlebotomy services to ensure proper specimen collection and handling.*


The sample is collected by BioReference medical staff



The medical staff bags the sample with the requisition and appropriate labels




Samples are transported to the laboratory




Online Results

Test results will be provided via a patient-friendly report format and will be accessible to the host organization and employees via BioReference's online Patient Portal.

Participant results are available in 2-3 days



Result Reports*



Educational Tools

Employees may have questions about test the testing process and what their results mean. BioReference is able to provide educational tools that include information on getting tested, how to access results, and what those results mean.



SCREENING EVENT OPTIONS

BioReference provides digital registration and online result access to government authorities. BioReference also offers site identification and set-up services, and phlebotomy services depending on host organization size and preference. Implementation of the steps listed below are completed within 7-10 days of the signing of the agreement.

Number of Employees	Site Identification	Site Set-Up/ Security/ Tables/Chairs	Appointment & Registration	Phlebotomy Services	Result Reporting
5-200	Host	BRLI or Host	BRLI	BRLI or Host	BRLI
150-1000	BRLI or Host	BRLI or Host	BRLI	BRLI	BRLI
1000-10,000	BRLI or Host	BRLI or Host	BRLI	BRLI	BRLI

* Depending on organization size.